Related Experiment Video
Updated: Aug 9, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Differences in human papillomavirus type may influence clinical outcome in early stage cervical cancer
Liselotte Dahlgren1, Fredrik Erlandsson, David Lindquist
1Department of Oncology-Pathology, Karolinska Institutet, CancerCentrumKarolinska, Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden. Liselotte.Dahlgren@ki.se
Background:
The presence of human papillomavirus (HPV), the HPV type and viral load in early stage cervical carcinoma were investigated in order to elucidate whether any of these factors were important for clinical outcome.
Patients And Methods:
Twelve patients who were disease-free 5 years after diagnosis were matched and compared with 12 patients who died within 2 years. The presence of HPV, HPV type and viral load in their tumours was examined by PCR.
Results:
The distribution and load of HPV was similar in the 2 patient groups. HPV-16 was, however, significantly more common in tumours of the surviving patients than in those of patients who died (88.9% and 18.2%, respectively, p = 0.0152).
Conclusion:
HPV-16 was significantly more common in early stage carcinomas of patients surviving more than 5 years in comparison to early stage carcinomas of patients with a poor prognosis.
Related Concept Videos
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mechanisms of Retrovirus-induced Cancers
Genital Herpes
Cancer
Cancer Prevention
Some...
Human Virome